New HPV vaccine ‘could prevent 90% of cervical cancers’

A new human papilloma virus (HPV) vaccine that is currently being developed could be effective in protecting women from up to 90 per cent of cervical cancers.

This is according to new research published in the journal Cancer Epidemiology, Biomarkers & Prevention.

The company behind this, Merck, said that the nine-valent vaccine has the potential to protect women against nine total types of HPV, which is five more than the current vaccine on the market.

"We wanted to study how many cervical pre-cancers could potentially be prevented by an investigational nine-valent HPV vaccine that provides protection against the HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58," explained Dr Elmar A. Joura, an associate professor of gynaecology at the Medical University of Vienna in Austria.

"Approximately 85 per cent or more of precancerous lesions of the cervix were attributed to the nine HPV types covered in the vaccine; therefore, if nine-valent HPV vaccination programs are effectively implemented, the majority of these lesions could be prevented."

HPV is a common and contagious infection that over three quarters of sexually active women will experience at some point in their lives, says the NHS.

It can lead to abnormal tissue growth and changes to cells in the cervix, which can lead to cervical cancer.

Posted by Alexandra GeorgeADNFCR-2094-ID-801752196-ADNFCR